A review of pharmaceutical occurrence and pathways in the aquatic environment in the context of a changing climate and the COVID-19 pandemic

• Published in: Analytical methods Vol. 13; no. 5; pp. 575 - 594
• Main Authors: O'Flynn, Dylan, Lawler, Jenny, Yusuf, Azeez, Parle-McDermott, Anne, Harold, Denise, Mc Cloughlin, Thomas, Holland, Linda, Regan, Fiona, White, Blánaid
• Format: Journal Article
• Language: English
• Published: England Royal Society of Chemistry 11.02.2021
• Subjects: Activated sludge; Animals; Aquatic environment; Aquatic Organisms - drug effects; bioactive properties; Biological activity; Ciprofloxacin; Clarithromycin; climate; Climate Change; Contaminants; COVID-19; COVID-19 - epidemiology; COVID-19 infection; Diclofenac; Drug Industry; Drugs; Ecotoxicology; education; Environmental impact; environmental law; Environmental regulations; European Union; Gemfibrozil; human health; Humans; Life cycles; Pandemics; Persistent Organic Pollutants - isolation & purification; Persistent Organic Pollutants - metabolism; Persistent Organic Pollutants - pharmacology; Pharmaceutical Preparations - isolation & purification; Pharmaceutical Preparations - metabolism; Pharmaceuticals; Plants - drug effects; Pollutants; prioritization; risk; SARS-CoV-2; Sulfamethoxazole; Surface stability; Surface water; Venlafaxine; Waste management; Wastewater treatment; Wastewater treatment plants; Water management; Water Pollutants, Chemical - isolation & purification; Water Pollutants, Chemical - metabolism; Water Pollutants, Chemical - pharmacology; Water pollution; Water Purification
• ISSN: 1759-9660; 1759-9679; 1759-9679
• DOI: 10.1039/d0ay02098b

Active pharmaceutical ingredients (APIs) are increasingly being identified as contaminants of emerging concern (CECs). They have potentially detrimental ecological and human health impacts but most are not currently subject to environmental regulation. Addressing the life cycle of these pharmaceutic...